BR0207216A - Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matriz - Google Patents
Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matrizInfo
- Publication number
- BR0207216A BR0207216A BR0207216-5A BR0207216A BR0207216A BR 0207216 A BR0207216 A BR 0207216A BR 0207216 A BR0207216 A BR 0207216A BR 0207216 A BR0207216 A BR 0207216A
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- alkyl
- pyrimidindione
- thiene
- matrix metalloproteinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
"DERIVADOS DE TIENO 2,3-D-PIRIMIDINDIONA COMO INIBIDORES DE METALOPROTEINASE MATRIZ". Inibidores de MMP-13 seletivos são pirimidinonas fundidas da fórmula ou um seu sal farmaceuticamente aceitável; em que: W, em conjunto com os átomos de carbono aos quais ele está ligado, forma um dirradical em anel de 5 membros Y é O, S, SO, SO~ 2~, NR^ 5^ ou CH~ 2~; O (O)~ n~ A é ou B é O ou NR^ 5^ ou A e B são considerados em conjunto para formar -C<sym>C-; R^ 1^, R^ 4^ e R^ 5^ são independentemente hidrogênio, alquila, alquenila, alquinila, (CH~ 2~)~ n~-arila, (CH~ 2~)~ n~-cicloalquila, alcanoílo C~ 1~-C~ 6~ ou (CH~ 2~)~ n~heteroarila; R^ 2^ e R^ 3^ são independentemente hidrogênio, alquila, alquenila , alquinila, CN, NO~ 2~, NR^ 4^R^ 5^, (CH~ 2~)~ n~-cicloalquila, (CH~ 2~)~ n~-arila ou (CH~ 2~)~ n~heteroarila; R^ 2^ pode ainda ser halo ; n é um número inteiro de 0 até 5; e R^ 4^ e R^ 5^ quando considerados em conjunto com o nitrogênio ao qual eles estão ligados completam um anel de 3 a 8 membros contendo átomos de carbono e contendo opcionalmente O, S ou N, e substituído ou não substituído; com a condição de que R^ 1^ e R^ 3^ não são ambos selecionados dentre hidrogênio e alquila C~ 1~-C~ 6~.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26875601P | 2001-02-14 | 2001-02-14 | |
PCT/IB2002/000204 WO2002064598A1 (en) | 2001-02-14 | 2002-01-18 | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0207216A true BR0207216A (pt) | 2004-03-09 |
Family
ID=23024328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0207216-5A BR0207216A (pt) | 2001-02-14 | 2002-01-18 | Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matriz |
Country Status (15)
Country | Link |
---|---|
US (1) | US20030004172A1 (pt) |
EP (1) | EP1370562A1 (pt) |
JP (1) | JP2004518732A (pt) |
BR (1) | BR0207216A (pt) |
CA (1) | CA2433778A1 (pt) |
DO (1) | DOP2002000337A (pt) |
GT (1) | GT200200017A (pt) |
HN (1) | HN2002000029A (pt) |
MX (1) | MXPA03004926A (pt) |
PA (1) | PA8538301A1 (pt) |
PE (1) | PE20020957A1 (pt) |
SV (1) | SV2003000882A (pt) |
TN (1) | TNSN02009A1 (pt) |
UY (1) | UY27159A1 (pt) |
WO (1) | WO2002064598A1 (pt) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2002000334A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
PT1401825E (pt) * | 2001-06-11 | 2009-10-23 | Virochem Pharma Inc | Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
EP1434585A1 (en) | 2001-10-12 | 2004-07-07 | Warner-Lambert Company LLC | Alkyne matrix metalloproteinase inhibitors |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
AU2003247024A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
EP1531904A1 (en) * | 2002-07-17 | 2005-05-25 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
BR0312736A (pt) * | 2002-07-17 | 2005-04-26 | Warner Lambert Co | Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib |
AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
EP1394159A1 (fr) * | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
JP2006504665A (ja) | 2002-08-13 | 2006-02-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体 |
MXPA05001783A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz. |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
MXPA05001785A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de cromona como inhibidores de las metaloproteinasas de matriz. |
WO2004014916A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
EP1530472A1 (en) * | 2002-08-13 | 2005-05-18 | Warner-Lambert Company LLC | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
WO2004014908A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
AU2003250465A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
JP2006501215A (ja) | 2002-08-13 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体 |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
AU2004207706B2 (en) * | 2003-01-29 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
JP2008094846A (ja) * | 2003-01-29 | 2008-04-24 | Takeda Chem Ind Ltd | チエノピリミジン化合物およびその用途 |
US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
US7570259B2 (en) | 2004-06-01 | 2009-08-04 | Intel Corporation | System to manage display power consumption |
AR051984A1 (es) | 2004-12-08 | 2007-02-21 | Bristol Myers Squibb Co | Compuestos heterociclicos como inhibidores del factor viia |
CA2644996A1 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
CA2660957C (en) * | 2006-08-23 | 2016-10-11 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
CA2670788A1 (en) | 2006-12-01 | 2008-06-12 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
EP1939197A1 (en) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
CA2685753A1 (en) * | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
AR077898A1 (es) | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
CA2855372C (en) * | 2011-11-11 | 2022-03-22 | Nimbus Apollo, Inc. | 2,4-dioxo-thieno[2,3-d]pyrimidinyl derivatives and pharmaceutical compositions thereof used as acc inhibitors |
CN105793267B (zh) * | 2013-10-07 | 2018-02-06 | 拜耳制药股份公司 | 环状噻吩并尿嘧啶甲酰胺类及其用途 |
UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
KR20180082556A (ko) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | 피라졸 acc 억제제 및 그의 용도 |
KR20180082557A (ko) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | 트리아졸 acc 억제제 및 그의 용도 |
SI3379933T1 (sl) | 2015-11-25 | 2023-07-31 | Gilead Apollo, Llc | Fungicidni sestavki, ki vsebujejo derivate 2,4-diokso-1,4-dihidrotieno (2,3-d)pirimidina |
HUE053175T2 (hu) | 2015-11-25 | 2021-06-28 | Gilead Apollo Llc | ACC-gátló észterek és azok alkalmazása |
JP6944462B2 (ja) | 2016-03-02 | 2021-10-06 | ギリアド アポロ, エルエルシー | チエノピリミジンジオンacc阻害剤の固体形態およびその生成のための方法 |
WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
CA3037642A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Aktiengesellschaft | N 3 -cyclically substituted thienouraciles and use thereof |
CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
CN110183464B (zh) * | 2019-05-31 | 2021-08-31 | 淮阴工学院 | 一种抗癌化合物艾斯替尼及其合成方法和应用 |
KR102649886B1 (ko) * | 2021-07-21 | 2024-03-22 | 충남대학교산학협력단 | 신규한 피리미딘-4-온 화합물 및 이를 포함하는 항암제 조성물 |
WO2024036183A1 (en) * | 2022-08-09 | 2024-02-15 | Vanderbilt University | Antagonists of 5-hydroxytryptamine receptor subtype 2b |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155665A (en) | 1961-04-26 | 1964-11-03 | Searle & Co | 4, 6-dialkyl-5, 7-diketothiazolo [4, 5-d] pyrimidine-2-carboxylic acid and derivatives thereof |
US3277093A (en) | 1965-08-02 | 1966-10-04 | Searle & Co | (optionally-2-substituted) 4-halophenyl-5, 7-diketo-6-alkylthiazolo[4, 5-d]pyrimidines |
GB8601371D0 (en) | 1986-01-21 | 1986-02-26 | Beecham Group Plc | Compounds |
US6140325A (en) * | 1993-08-19 | 2000-10-31 | Takeda Chemical Industries, Ltd. | Thienopyrimidine derivatives, their production and use |
US6048863A (en) * | 1994-04-19 | 2000-04-11 | Takeda Chemical Industries, Ltd. | Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use |
KR970707131A (ko) * | 1994-11-08 | 1997-12-01 | 다께다 구니오 | 티에노피리딘 또는 티에노피리미딘 유도체 및 그의 용도(thienopyridine or thienopyrimidine derivatives and their use) |
US5792767A (en) * | 1995-01-27 | 1998-08-11 | Abbott Laboratories | Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists |
ATE228518T1 (de) * | 1996-06-06 | 2002-12-15 | Otsuka Pharma Co Ltd | Amid derivate |
SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
US6469014B1 (en) * | 1997-05-28 | 2002-10-22 | Astrazeneca Ab | Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy |
US6166019A (en) * | 1998-07-16 | 2000-12-26 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
US6300334B1 (en) * | 1998-08-28 | 2001-10-09 | Astrazeneca Ab | Thieno[2,3-d]pyrimidine-2,4-diones |
DE19940494C1 (de) * | 1999-08-26 | 2001-02-15 | Ibfb Gmbh Privates Inst Fuer B | Mehrcyclische Pyrimidin-2,4(1H,3H)-dione mit funktionalisierten Alkylresten in 1- und/oder 3-Position, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen |
PA8539501A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
US6924276B2 (en) * | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
WO2004014916A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
US20050004111A1 (en) * | 2003-01-03 | 2005-01-06 | Aventis Pharma Deutschland Gmbh | Selective MMP-13 inhibitors |
-
2002
- 2002-01-18 MX MXPA03004926A patent/MXPA03004926A/es unknown
- 2002-01-18 JP JP2002564529A patent/JP2004518732A/ja not_active Abandoned
- 2002-01-18 WO PCT/IB2002/000204 patent/WO2002064598A1/en not_active Application Discontinuation
- 2002-01-18 CA CA002433778A patent/CA2433778A1/en not_active Abandoned
- 2002-01-18 BR BR0207216-5A patent/BR0207216A/pt not_active IP Right Cessation
- 2002-01-18 EP EP02711123A patent/EP1370562A1/en not_active Withdrawn
- 2002-02-01 DO DO2002000337A patent/DOP2002000337A/es unknown
- 2002-02-05 PA PA20028538301A patent/PA8538301A1/es unknown
- 2002-02-07 GT GT200200017A patent/GT200200017A/es unknown
- 2002-02-08 UY UY27159A patent/UY27159A1/es not_active Application Discontinuation
- 2002-02-11 HN HN2002000029A patent/HN2002000029A/es unknown
- 2002-02-12 PE PE2002000110A patent/PE20020957A1/es not_active Application Discontinuation
- 2002-02-13 TN TNTNSN02009A patent/TNSN02009A1/fr unknown
- 2002-02-13 SV SV2002000882A patent/SV2003000882A/es unknown
- 2002-02-13 US US10/075,073 patent/US20030004172A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SV2003000882A (es) | 2003-01-13 |
GT200200017A (es) | 2002-11-15 |
US20030004172A1 (en) | 2003-01-02 |
MXPA03004926A (es) | 2005-02-14 |
WO2002064598A1 (en) | 2002-08-22 |
EP1370562A1 (en) | 2003-12-17 |
TNSN02009A1 (fr) | 2005-12-23 |
JP2004518732A (ja) | 2004-06-24 |
DOP2002000337A (es) | 2002-08-15 |
HN2002000029A (es) | 2003-02-14 |
PA8538301A1 (es) | 2002-09-17 |
PE20020957A1 (es) | 2002-11-08 |
UY27159A1 (es) | 2002-09-30 |
CA2433778A1 (en) | 2002-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0207216A (pt) | Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matriz | |
BR0207209A (pt) | Inibidores de metaloproteinase de matriz de pirimidina | |
BR0207863A (pt) | Inibidores piridìnicos de metaloproteinases da matriz | |
BRPI0408284B8 (pt) | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos | |
HUP0300616A2 (hu) | Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
BR0115478A (pt) | Aminotiazós e o uso dos mesmos como antagonistas do receptor da adenosina | |
WO2001077107A8 (en) | Oxazole derivatives and their uses as tyrosine kinase inhibitors | |
DK1150944T3 (da) | N2-phenylamidinderivater | |
NO20034931L (no) | Substituerte 2-pyridin-cykloheksan-1,4-diaminderivater | |
TR200100623T2 (tr) | 5-Tia-w-ikameli fenil-prostaglandin türevleri, bunları üretme yöntemleri ve müessir madde olarak bunları ihtiva eden ilaçlar | |
BR0112456A (pt) | Compostos de piperidina para uso como inibidores de ccr-3 | |
DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
MXPA02012076A (es) | Compuestos quimicos. | |
ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
RS50229B (sr) | Analozi vitamina d3 | |
DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
DE60121587D1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
BR0208169A (pt) | Composto quìmicos | |
EA200100618A1 (ru) | Антагонист витронектинового рецептора | |
BR0015333A (pt) | Derivados de isoxazol como inibidores de fosfodiesterase vii | |
DE60110124D1 (de) | Kondensierte pyrazindionderivate als pde inhibitoren | |
DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
CO5261576A1 (es) | Compuestos | |
EA200101180A1 (ru) | Производные тио-оксиндола | |
FI961793A0 (fi) | Muistia parantavina aineina käyttökelpoiset 3-aryyli-4-alkyyli- ja 4,5-dialkyyli 4H-1,2,4-triatsolit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |